GlassScriptPhysician profile
Laura Shepherd
NPI 1457839342
$13,250.64
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,550 · 2022: $3,723 · 2023: $4,157 · 2024: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,977.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,489.01 | 2021-2024 | |
| Ucb, INC. | $1,121.83 | 2021-2024 | Briviact, Rystiggo, Fintepla |
| Livanova USA, INC. | $760.38 | 2021 | |
| Lilly USA, LLC | $698.22 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Neurelis, INC. | $694.78 | 2021-2024 | Valtoco |
| Amgen INC. | $642.13 | 2021-2023 | Aimovig |
| Biogen, INC. | $605.66 | 2021-2024 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $550.33 | 2021-2024 | Austedo Xr |
| Argenx US, INC. | $457.57 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $450.10 | 2021-2024 | |
| Pfizer INC. | $449.54 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $425.99 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $425.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $386.65 | 2021-2023 | |
| Eisai INC. | $373.99 | 2021-2024 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.